US5498631B1 - Method for treatment of menopausal and premenstrual symptoms - Google Patents

Method for treatment of menopausal and premenstrual symptoms Download PDF

Info

Publication number
US5498631B1
US5498631B1 US28367894A US5498631B1 US 5498631 B1 US5498631 B1 US 5498631B1 US 28367894 A US28367894 A US 28367894A US 5498631 B1 US5498631 B1 US 5498631B1
Authority
US
United States
Prior art keywords
menopausal
treatment
premenstrual symptoms
premenstrual
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
Other languages
English (en)
Inventor
Sherwood L Aldercreutz Gorbach
Barry R Goldin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNIVERSITY SCHOOL OF MEDICINE
Tufts University
Original Assignee
Tufts University School of Medicine Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21957593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US5498631(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tufts University School of Medicine Hospital Inc filed Critical Tufts University School of Medicine Hospital Inc
Priority to US08283678 priority Critical patent/US5498631B1/en
Publication of US5498631A publication Critical patent/US5498631A/en
Application granted granted Critical
Publication of US5498631B1 publication Critical patent/US5498631B1/en
Assigned to TRUSTEES OF TUFTS COLLEGE reassignment TRUSTEES OF TUFTS COLLEGE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GOLDIN, BARRY R., GORBACH, SHERWOOD L., ADLERCREUTZ, HERMAN
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
US08283678 1993-04-16 1994-08-01 Method for treatment of menopausal and premenstrual symptoms Expired - Fee Related US5498631B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08283678 US5498631B1 (en) 1993-04-16 1994-08-01 Method for treatment of menopausal and premenstrual symptoms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4900693A 1993-04-16 1993-04-16
US08283678 US5498631B1 (en) 1993-04-16 1994-08-01 Method for treatment of menopausal and premenstrual symptoms

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US4900693A Continuation 1993-04-16 1993-04-16

Publications (2)

Publication Number Publication Date
US5498631A US5498631A (en) 1996-03-12
US5498631B1 true US5498631B1 (en) 1998-03-03

Family

ID=21957593

Family Applications (1)

Application Number Title Priority Date Filing Date
US08283678 Expired - Fee Related US5498631B1 (en) 1993-04-16 1994-08-01 Method for treatment of menopausal and premenstrual symptoms

Country Status (5)

Country Link
US (1) US5498631B1 (fr)
EP (1) EP0693927A4 (fr)
AU (1) AU6635994A (fr)
CA (1) CA2160371A1 (fr)
WO (1) WO1994023716A1 (fr)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003084A1 (fr) * 1996-07-18 1998-01-29 Nutricor, Inc. Preparations alimentaires nourrissantes
WO1998021947A1 (fr) * 1996-11-18 1998-05-28 Internutria, Inc. Composition destinee au traitement de symptomes nocturnes de transition reproductive persistante
WO1998021946A1 (fr) * 1996-11-18 1998-05-28 Internutria, Inc. Composition et traitement des symptomes de transition reproductive persistante
US5830887A (en) * 1992-05-19 1998-11-03 Novogen Research Pty. Ltd. Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US5855892A (en) * 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
WO1999017767A1 (fr) * 1997-10-03 1999-04-15 Wake Forest University Procedes de traitement et de prevention de l'endometriose a l'aide de phytoestrogenes
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
US6040333A (en) * 1996-07-30 2000-03-21 Energetics, Inc. Dietary supplements
US6174542B1 (en) 1999-07-01 2001-01-16 Pms Mood Food, Inc. Dietary supplements and food products for treating symptoms of PMS
US6326366B1 (en) 2000-08-22 2001-12-04 Protein Technologies International Hormone replacement therapy
US6340703B1 (en) * 1997-05-01 2002-01-22 Novogen, Inc. Treatment or prevention of osteoporosis
US20020091110A1 (en) * 1999-02-24 2002-07-11 Geza Bruckner Dietary compositions
WO2002085396A1 (fr) * 2001-04-24 2002-10-31 President And Fellows Of Harvard College Inhibition de la kinase jun
US6482448B2 (en) 1998-07-16 2002-11-19 Aaron Tabor Soy formulations and their use for promoting health
US20020198248A1 (en) * 1996-08-30 2002-12-26 Novogen Research Pty Limited Therapeutic methods and compositions involving isoflavones
US6509043B1 (en) 1998-11-25 2003-01-21 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases
US6599536B1 (en) 1998-03-26 2003-07-29 Novogen Research Pty Ltd Therapy of estrogen-associated disorders
US20030157225A1 (en) * 2000-01-21 2003-08-21 Husband Alan James Food product and process
US6617349B2 (en) 2000-08-16 2003-09-09 Lipton, Division Of Conopco, Inc. Blends of isoflavones and flavones
US6630178B1 (en) 1998-11-25 2003-10-07 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
US20040147551A1 (en) * 1999-09-06 2004-07-29 Novogen Research Pty Ltd. Compositions and therapeutic methods involving isoflavones and analogues thereof
US20040147594A1 (en) * 2002-07-24 2004-07-29 Setchell Kenneth David Reginal Compositions and products containing R-equol, and methods for their making
US20040198674A1 (en) * 2000-03-29 2004-10-07 Lycored Natural Products Industries Ltd. Compositions for preventing hormone induced adverse effects
US20050036962A1 (en) * 1997-12-24 2005-02-17 Novogen Research Pty. Ltd. Compositions and method for protecting skin from UV induced immunosuppression and skin damage
US20050119301A1 (en) * 2001-03-16 2005-06-02 Alan Husband Treatment of restenosis
US20050245492A1 (en) * 2004-04-28 2005-11-03 Lephart Edwin D Use of equol for treating skin diseases
US20050261247A1 (en) * 2001-04-24 2005-11-24 Hotamisligil Gokhan S Inhibition of jun kinase
US7025998B2 (en) 2003-05-30 2006-04-11 Rotta Research Laboratorium S.P.A. Phytoestrogens and probiotic for women's health
US7033621B1 (en) 1997-04-28 2006-04-25 Novogen, Inc. Isoflavone compositions produced from legumes
US20060122262A1 (en) * 2002-10-29 2006-06-08 Lephart Edwin D Use of equol for treating androgen mediated diseases
EP1743881A1 (fr) 1999-04-30 2007-01-17 G.J. Consultants Pty Ltd Phényl-benzyl-cétones
US20070219515A1 (en) * 2006-03-14 2007-09-20 The Procter & Gamble Company Absorbent articles with lotions
US7312344B2 (en) 2001-03-08 2007-12-25 Novogen Research Pty Limited Dimeric isoflavones
US20090233999A1 (en) * 1999-09-06 2009-09-17 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
US20100076071A1 (en) * 2002-07-24 2010-03-25 Edwin Douglas Lephart Use of equol for treating skin diseases
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
WO2018057737A1 (fr) 2016-09-22 2018-03-29 Cash Alan B Méthode pour soulager les symptômes du spm
KR20180118177A (ko) * 2016-03-08 2018-10-30 오츠카 세이야쿠 가부시키가이샤 여성 특유의 신체적 및/또는 정신적 불쾌 증상의 개선제

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506211A (en) * 1994-05-09 1996-04-09 The Uab Research Foundation Genistein for use in inhibiting osteroclasts
CA2261764A1 (fr) * 1996-07-30 1998-02-05 Jeffrey B. Blumberg Complements alimentaires
AU2007201805B2 (en) * 1996-08-30 2009-03-26 Novogen Research Pty Ltd Therapeutic methods and compositions involving isoflavones
AU2004224982B2 (en) * 1996-08-30 2007-09-13 Novogen Research Pty Ltd Therapeutic methods and compositions involving isoflavones
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
AU779210B2 (en) * 1997-05-01 2005-01-13 Novogen Inc Treatments or prevention of menopausal symptoms and osteoporosis
US6083526A (en) * 1997-05-22 2000-07-04 Gorbach; Sherwood L. Use of isoflavonoids in the treatment or prevention of postpartum depression
US6060070A (en) * 1997-06-11 2000-05-09 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of aging skin and wrinkles
US6716424B1 (en) * 1997-08-08 2004-04-06 Otsuka Pharmaceutical Co., Ltd. Streptococcus and isoflavone-containing composition
US6004558A (en) * 1998-02-25 1999-12-21 Novogen, Inc. Methods for treating cancer with legume plant extracts
AU3456499A (en) * 1998-03-30 1999-10-18 University Of Mississippi, The Isoflavones for treating giardiasis and malaria
WO2004014886A1 (fr) * 2002-08-07 2004-02-19 University Of Mississippi Agents anti-giardiase et leur utilisation
US20080108696A1 (en) 2006-08-02 2008-05-08 Brinton Roberta D Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases
CA2659905A1 (fr) * 2006-08-02 2008-02-07 Roberta Diaz Brinton Formulations phyto-oestrogeniques pour soulager ou prevenir des maladies neurodegeneratives
US8680140B2 (en) 2006-08-02 2014-03-25 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3864362A (en) * 1970-05-27 1975-02-04 Chinoin Gyogyszer Es Vegyeszet Iso flavones
JPS6048924A (ja) * 1983-08-24 1985-03-16 Takeda Chem Ind Ltd 骨粗鬆症治療剤
IT1244697B (it) * 1991-02-01 1994-08-08 Chiesi Farma Spa Associazione farmaceutica per la prevenzione e il trattamento dell'osteoporosi post-menopausale
ATE275959T1 (de) * 1992-05-19 2004-10-15 Graham Edmund Kelly Verwendung von isoflavon phyto-östrogen extrakten von soja oder klee

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045155B2 (en) 1992-05-19 2006-05-16 Novogen Research Pty Ltd. Dietary supplements comprising soy hypocotyls containing at least one isoflavone
US20040106561A1 (en) * 1992-05-19 2004-06-03 Novogen Research Pty. Ltd. Health supplement
US6987098B2 (en) 1992-05-19 2006-01-17 Novogen Research Pty. Ltd. Health supplement
USRE40792E1 (en) 1992-05-19 2009-06-23 Novogen Research Pty Ltd Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US20070179099A1 (en) * 1992-05-19 2007-08-02 Novogen Research Pty Ltd. Methods of cholesterol reduction using isoflavones
US6497906B1 (en) 1992-05-19 2002-12-24 Novogen Research Pty. Ltd. Dietary supplements comprising soy hypocotyls containing at least one isoflavone
US6642212B1 (en) * 1992-05-19 2003-11-04 Novogen Research Pty. Ltd. Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US20030078214A1 (en) * 1992-05-19 2003-04-24 Novogen Research Pty. Ltd. Dietary supplements comprising soy hypocotyls containing at least one isoflavone
US20040048812A1 (en) * 1992-05-19 2004-03-11 Novogen Research Pty. Ltd. Health supplement
US5830887A (en) * 1992-05-19 1998-11-03 Novogen Research Pty. Ltd. Health supplements containing phyto-oestrogens, analogues or metabolites thereof
WO1998003084A1 (fr) * 1996-07-18 1998-01-29 Nutricor, Inc. Preparations alimentaires nourrissantes
US20040013743A1 (en) * 1996-07-30 2004-01-22 Jackson Sherry D. Dietary supplements
US6040333A (en) * 1996-07-30 2000-03-21 Energetics, Inc. Dietary supplements
US7202273B2 (en) * 1996-08-30 2007-04-10 Novogen Research Pty Ltd Therapeutic methods and compositions involving isoflavones
US20020198248A1 (en) * 1996-08-30 2002-12-26 Novogen Research Pty Limited Therapeutic methods and compositions involving isoflavones
US20030018060A1 (en) * 1996-08-30 2003-01-23 Novogen Research Pty Limited Therapeutic methods and compositions involving isoflavones
WO1998021946A1 (fr) * 1996-11-18 1998-05-28 Internutria, Inc. Composition et traitement des symptomes de transition reproductive persistante
WO1998021947A1 (fr) * 1996-11-18 1998-05-28 Internutria, Inc. Composition destinee au traitement de symptomes nocturnes de transition reproductive persistante
US7033621B1 (en) 1997-04-28 2006-04-25 Novogen, Inc. Isoflavone compositions produced from legumes
US20020035074A1 (en) * 1997-05-01 2002-03-21 Novogen, Inc. Treatment or prevention of menopausal symptoms and osteoporosis
US6340703B1 (en) * 1997-05-01 2002-01-22 Novogen, Inc. Treatment or prevention of osteoporosis
JP2008024723A (ja) * 1997-05-01 2008-02-07 Novogen Inc 更年期症状および骨粗鬆症の治療または予防
US5855892A (en) * 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
WO1999017767A1 (fr) * 1997-10-03 1999-04-15 Wake Forest University Procedes de traitement et de prevention de l'endometriose a l'aide de phytoestrogenes
US20050036962A1 (en) * 1997-12-24 2005-02-17 Novogen Research Pty. Ltd. Compositions and method for protecting skin from UV induced immunosuppression and skin damage
US20080038387A1 (en) * 1998-03-26 2008-02-14 Novogen Research Pty Ltd Therapy of estrogen-associated disorders
US6599536B1 (en) 1998-03-26 2003-07-29 Novogen Research Pty Ltd Therapy of estrogen-associated disorders
US6482448B2 (en) 1998-07-16 2002-11-19 Aaron Tabor Soy formulations and their use for promoting health
US6509043B1 (en) 1998-11-25 2003-01-21 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases
US6630178B1 (en) 1998-11-25 2003-10-07 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
US20020091110A1 (en) * 1999-02-24 2002-07-11 Geza Bruckner Dietary compositions
EP1743881A1 (fr) 1999-04-30 2007-01-17 G.J. Consultants Pty Ltd Phényl-benzyl-cétones
US6174542B1 (en) 1999-07-01 2001-01-16 Pms Mood Food, Inc. Dietary supplements and food products for treating symptoms of PMS
US7488494B2 (en) 1999-09-06 2009-02-10 Novogen Research Pty Ltd. Compositions and therapeutic methods involving isoflavones and analogues thereof
US20040147551A1 (en) * 1999-09-06 2004-07-29 Novogen Research Pty Ltd. Compositions and therapeutic methods involving isoflavones and analogues thereof
US20060106220A1 (en) * 1999-09-06 2006-05-18 Novogen Research Pty. Ltd. Compositions and therapeutic methods involving isoflavones and analogues thereof
US20090233999A1 (en) * 1999-09-06 2009-09-17 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
US20030157225A1 (en) * 2000-01-21 2003-08-21 Husband Alan James Food product and process
US20040198674A1 (en) * 2000-03-29 2004-10-07 Lycored Natural Products Industries Ltd. Compositions for preventing hormone induced adverse effects
US6617349B2 (en) 2000-08-16 2003-09-09 Lipton, Division Of Conopco, Inc. Blends of isoflavones and flavones
US6326366B1 (en) 2000-08-22 2001-12-04 Protein Technologies International Hormone replacement therapy
US7312344B2 (en) 2001-03-08 2007-12-25 Novogen Research Pty Limited Dimeric isoflavones
US20050119301A1 (en) * 2001-03-16 2005-06-02 Alan Husband Treatment of restenosis
US20070207137A1 (en) * 2001-04-24 2007-09-06 Harvard University, President And Fellows Of Harvard College Inhibition of Jun Kinase
US20050261247A1 (en) * 2001-04-24 2005-11-24 Hotamisligil Gokhan S Inhibition of jun kinase
US7232897B2 (en) 2001-04-24 2007-06-19 Harvard University, President And Fellows Of Harvard College Compositions and methods for modulating NH2-terminal Jun Kinase activity
WO2002085396A1 (fr) * 2001-04-24 2002-10-31 President And Fellows Of Harvard College Inhibition de la kinase jun
US7396855B2 (en) 2002-07-24 2008-07-08 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US9018247B2 (en) 2002-07-24 2015-04-28 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
US8048913B2 (en) 2002-07-24 2011-11-01 Australian Health & Nutrition Assoc. Ltd. Compositions and products containing S-equol, and methods for their making
US20090018185A1 (en) * 2002-07-24 2009-01-15 Australian Health & Nutrition Association Limited Compositions and products containing s-equol, and methods for their making
US20040235758A1 (en) * 2002-07-24 2004-11-25 Setchell Kenneth David Reginald Compositions and products containing S-equol, and methods for their making
US20040147594A1 (en) * 2002-07-24 2004-07-29 Setchell Kenneth David Reginal Compositions and products containing R-equol, and methods for their making
US9173866B2 (en) 2002-07-24 2015-11-03 Children's Hospital Medical Center Compositions and products containing R-equol, and methods for their making
US20100076071A1 (en) * 2002-07-24 2010-03-25 Edwin Douglas Lephart Use of equol for treating skin diseases
US9408824B2 (en) 2002-07-24 2016-08-09 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US7960432B2 (en) 2002-07-24 2011-06-14 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US8450364B2 (en) 2002-10-29 2013-05-28 Brigham Young University Use of equol for treating androgen mediated diseases
US9408825B2 (en) 2002-10-29 2016-08-09 Brigham Young University Use of equol for treating androgen mediated diseases
US20100087519A1 (en) * 2002-10-29 2010-04-08 Brigham Young University Use of equol for treating androgen mediated diseases
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US10111855B2 (en) 2002-10-29 2018-10-30 Brigham Young University Use of equol for treating androgen mediated diseases
US8153684B2 (en) 2002-10-29 2012-04-10 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
US9089547B2 (en) 2002-10-29 2015-07-28 Brigham Young University Use of equol for treating androgen mediated diseases
US9889116B2 (en) 2002-10-29 2018-02-13 Bringham Young University Use of equol for treating androgen mediated diseases
US20060122262A1 (en) * 2002-10-29 2006-06-08 Lephart Edwin D Use of equol for treating androgen mediated diseases
US7025998B2 (en) 2003-05-30 2006-04-11 Rotta Research Laboratorium S.P.A. Phytoestrogens and probiotic for women's health
US20050245492A1 (en) * 2004-04-28 2005-11-03 Lephart Edwin D Use of equol for treating skin diseases
US20070219515A1 (en) * 2006-03-14 2007-09-20 The Procter & Gamble Company Absorbent articles with lotions
KR20180118177A (ko) * 2016-03-08 2018-10-30 오츠카 세이야쿠 가부시키가이샤 여성 특유의 신체적 및/또는 정신적 불쾌 증상의 개선제
CN109069476A (zh) * 2016-03-08 2018-12-21 大塚制药株式会社 女性特有的身体和/或精神不快症状的改善剂
EP3427731A4 (fr) * 2016-03-08 2019-10-09 Otsuka Pharmaceutical Co., Ltd. Agent d'amélioration de symptôme physique et/ou mental désagréable spécifique de la femme
WO2018057737A1 (fr) 2016-09-22 2018-03-29 Cash Alan B Méthode pour soulager les symptômes du spm
US11071722B2 (en) 2016-09-22 2021-07-27 Alan B. Cash Method to alleviate the symptoms of PMS
US11865092B2 (en) 2016-09-22 2024-01-09 Alan B. Cash Method to alleviate the symptoms of PMS

Also Published As

Publication number Publication date
EP0693927A4 (fr) 1997-05-28
US5498631A (en) 1996-03-12
AU6635994A (en) 1994-11-08
WO1994023716A1 (fr) 1994-10-27
CA2160371A1 (fr) 1994-10-27
EP0693927A1 (fr) 1996-01-31

Similar Documents

Publication Publication Date Title
US5498631B1 (en) Method for treatment of menopausal and premenstrual symptoms
EP0831924A4 (fr) Procede de traitement de l'asthme
ZA977564B (en) Method of treatment
EP0933803A4 (fr) Procede de traitement au plasma
HUP9602938A2 (en) Improved composition and method for acid gas treatment
GB9218027D0 (en) Novel method of treatment
GB9424913D0 (en) Enhancement of treatment processes
ZA973988B (en) Method of treatment
GB9618341D0 (en) Method of treatment
GB9202196D0 (en) Method of treatment
GB9507825D0 (en) Method of treatment
GB9400657D0 (en) Treatment of gas mixtures
GB9415902D0 (en) Method of treatment
HU9401479D0 (en) Method for treatment of molfen metals
GB9407335D0 (en) Method of treatment
GB9201391D0 (en) Method of treatment
GB9218597D0 (en) Novel method of treatment
GB9414652D0 (en) Method of treatment
GB9321971D0 (en) Method of treatment
GB9307004D0 (en) Method of treatment
GB9321796D0 (en) Method of treatment
GB9311068D0 (en) Treatment of gas
GB9309789D0 (en) Treatment of gas
GB9326020D0 (en) Novel method of treatment
GB9308853D0 (en) Novel method of treatment

Legal Events

Date Code Title Description
RR Request for reexamination filed

Effective date: 19970423

B1 Reexamination certificate first reexamination
FEPP Fee payment procedure

Free format text: PAT HLDR NO LONGER CLAIMS SMALL ENT STAT AS INDIV INVENTOR (ORIGINAL EVENT CODE: LSM1); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: TRUSTEES OF TUFTS COLLEGE, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GORBACH, SHERWOOD L.;GOLDIN, BARRY R.;ADLERCREUTZ, HERMAN;REEL/FRAME:010288/0546;SIGNING DATES FROM 19990920 TO 19991004

DI Adverse decision in interference

Effective date: 20011101

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

REMI Maintenance fee reminder mailed
FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 20040312

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362